InspireMD, Inc. (NSPR): Entry into a Material Definitive Agreement

InspireMD, Inc. (NSPR) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 InspireMD Announces Amendments to Certain Series J and Series K Warrants, Providing Potential Gross Proceeds of Up to $11 Million - Amendments align trigger event of existing warrants with anticipated FDA approval of CGuard Prime 80 cm, which the Company continues to

Original reporting
Published Sep 21, 2026, 1:12 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 21, 2026, 1:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$NSPR
Neutral
medium confidence
Mentioned
$NSPR
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$NSPRNeutralLow
01

Why it matters

The filing provides new financing terms that could become material if the regulatory milestone is met, but the immediate market impact is modest.

02

Market read

The news is relevant for investors focused on FDA‑driven biotech catalysts and warrant‑related financing structures.

03

What to watch

The amendment does not increase the total number of warrants, and the company still faces cash‑runway constraints.

Relevance 6/10Novelty 7/10Timing: today

Background

InspireMD filed an 8‑K announcing amendments to existing warrants, linking them to a pending FDA decision for its CGuard Prime 80 cm device.

Company-level read

Ticker impact

$NSPRNeutralMedium confidence
Context

InspireMD amended Series J and K warrants to align exercise terms with the anticipated FDA approval of CGuard Prime 80 cm, potentially providing up to $11 million of gross proceeds.

Expected impact

Potential modest upside if FDA approval is confirmed; limited downside risk.

Evidence & confidence

The amendment ties warrant exercise to a regulatory milestone, but no immediate cash is raised and the outcome depends on FDA approval.

Market effects

May boost the carotid stent/vascular device sector if FDA approval is achieved.

Primarily U.S. biotech market; limited broader regional effect.

Limited to investors tracking FDA‑driven biotech catalysts.

Counterpoint

If FDA approval is delayed, the warrant amendment could be seen as a financing stop‑gap with limited upside.

Key entities

  • InspireMD, Inc.

    Developer of CGuard® Prime carotid stent system.

Related articles

$NSPRHighAI 8/10

InspireMD (NSPR) Q3 2026 Earnings Call Transcript

InspireMD (NSPR) announced FDA approval for its CGuard Prime TransCarotid Stent System, expanding U.S. market access by 40,000 annual procedures. Q3 2026 international revenue grew 9% YoY to $2.2M. The company plans commercial execution and cost alignment, with a 20% workforce reduction. FDA submission for the CGuard Prime 135 CAS delivery system is expected by year-end.

$NSPRLow

InspireMD Inc (NSPR) (Q3 2026) Earnings Call Highlights: FDA Nod for CGuard Prime Reopens

InspireMD (NSPR) reported Q3 2026 revenue of $2.2M, down 11% YoY, with gross margin at 10.7%. The company received FDA approval for CGuard Prime, expecting immediate sales due to pent-up demand. Cash position is $19.2M, with potential $10M from warrant exercises. A workforce reduction cut expenses by 27%. The US market opportunity is expanded by 40,000 annual procedures. No formal guidance was provided.

$NSPRHigh

InspireMD Reports Third Quarter 2026 Financial Results

InspireMD, Inc. (NSPR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 InspireMD Reports Third Quarter 2026 Financial Results - Received FDA approval of CGuard® Prime for Transcarotid Arterial Revascularization (TCAR) procedures, expected to approximately double the U.S. addressable market - - Company to host investor conference call to

$NSPRHighAI 8/10

InspireMD Announces FDA Approval of the CGuard® Prime TransCarotid Stent System for Transcarotid Artery Revascularization (TCAR) Procedures

InspireMD, Inc. (NSPR) filed an SEC Form 8-K — Other Events. Exhibit 99.1 InspireMD Announces FDA Approval of the CGuard ® Prime TransCarotid Stent System for Transcarotid Artery Revascularization (TCAR) Procedures - Approval doubles the CGuard Prime platform’s total addressable market in the U.S. with additional access to over 35,000 TCAR